TCTR20221113004已完成不适用
The Real-world Clinical Outcomes of Favipiravir Treatment in Mild to Moderate COVID-19 Patients in Single Outpatient Visit Followed by Home Isolation: a Multicenter, case-control Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,037
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1.Confirmed SARS-COV-2 infected cases by Reverse Transcriptase-Polymerase Chain Reaction or Rapid antigen testing from respiratory specimens which were treated with outpatients, home isolation, or lived in quarantine facilities
- •2.Mild to moderate illness
- •3.Participants accept informed consent
排除标准
- •1.Age less than 20-year-old
- •2.Who lives in long-term facilities, or prison
- •3. Patients who need hospitalization on the initial day
- •3.Severe or critical COVID-19
- •3.1respiratory rate > 30 / min
- •3.2SpO2 less than 95%
- •3.3Patients who need oxygen therapy
- •3.4Respiratory failure
- •3.5Shock or BP<90/60
- •3.6Multi-organ failure
- •3.7WHO clinical progression scale more than or equal to 3
- •4. Pregnant or breast-feeding conditions
研究者
相似试验
招募中
3 期
Evaluation the effects of Favipiravir in COVID-19 patientsCOVID-19 pneumonia.COVID-19, virus identifiedU07.1IRCT20151227025726N14Shahid Beheshti University of Medical Sciences84
已完成
3 期
Favipiravir effectiveness in patients undergoing COVID19 Acute respiratory distress syndrome (ARDS)covid positive.Coronavirus infection, unspecifiedB34.2IRCT20150107020592N26Masih Daneshvari Hospital20
招募中
3 期
The therapeutic effect of Favipiravir in COVID-19 patientsIRCT20211004052664N1Shahid Beheshti University of Medical Sciences80
招募中
3 期
The effects of Favipiravir and Lopinavir/Ritonavir in treatment COVID-19IRCT20200506047323N3Bandare-abbas University of Medical Sciences60
已完成
3 期
Phase III Clinical Study on Favipiravir in Patients with Severe Fever with Thrombocytopenia SyndromeSevere Fever with Thrombocytopenia Syndrome (SFTS)JPRN-jRCT2080223816FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)30